Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

TCR2 Therapeutics

DB:2K7
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
2K7
DB
$168M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. The last earnings update was 6 days ago. More info.


Add to Portfolio Compare Print
  • TCR2 Therapeutics has significant price volatility in the past 3 months.
2K7 Share Price and Events
7 Day Returns
-3.1%
DB:2K7
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-57.3%
DB:2K7
-13.2%
DE Biotechs
-20.9%
DE Market
2K7 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
TCR2 Therapeutics (2K7) -3.1% -37.2% -55.4% -57.3% - -
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • 2K7 underperformed the Biotechs industry which returned -13.2% over the past year.
  • 2K7 underperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is TCR2 Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for TCR2 Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €6.25.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for TCR2 Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are TCR2 Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:2K7 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-4.62
NasdaqGS:TCRR Share Price ** NasdaqGS (2020-04-03) in USD $7.01
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of TCR2 Therapeutics.

DB:2K7 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:TCRR Share Price ÷ EPS (both in USD)

= 7.01 ÷ -4.62

-1.52x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • TCR2 Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • TCR2 Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does TCR2 Therapeutics's expected growth come at a high price?
Raw Data
DB:2K7 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.52x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
-5.1%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for TCR2 Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on TCR2 Therapeutics's assets?
Raw Data
DB:2K7 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $6.69
NasdaqGS:TCRR Share Price * NasdaqGS (2020-04-03) in USD $7.01
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:2K7 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:TCRR Share Price ÷ Book Value per Share (both in USD)

= 7.01 ÷ 6.69

1.05x

* Primary Listing of TCR2 Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • TCR2 Therapeutics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess TCR2 Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. TCR2 Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is TCR2 Therapeutics expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-5.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is TCR2 Therapeutics expected to grow at an attractive rate?
  • Unable to compare TCR2 Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare TCR2 Therapeutics's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare TCR2 Therapeutics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:2K7 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:2K7 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts -5.1%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:2K7 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:2K7 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 128 -57 -85 5
2023-12-31 36 -140 -121 4
2022-12-31 4 -129 -121 5
2021-12-31 0 -99 -95 6
2020-12-31 0 -62 -67 6
2020-04-05
DB:2K7 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -41 -97
2019-09-30 -38 -96
2019-06-30 -32 -100
2019-03-31 -27 -107
2018-12-31 -19 -62
2018-09-30 -17 -55
2017-12-31 -12 -15

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • TCR2 Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if TCR2 Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:2K7 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from TCR2 Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2K7 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -1.82 -0.80 -2.84 2.00
2023-12-31 -3.07 -1.83 -3.71 3.00
2022-12-31 -3.43 -1.97 -4.74 3.00
2021-12-31 -3.13 -2.04 -4.03 5.00
2020-12-31 -2.63 -2.14 -3.01 5.00
2020-04-05
DB:2K7 Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -4.62
2019-09-30 -6.29
2019-06-30 -10.67
2019-03-31 -29.77
2018-12-31 -98.53
2018-09-30 -99.14
2017-12-31 -39.94

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if TCR2 Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess TCR2 Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
TCR2 Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has TCR2 Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare TCR2 Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • TCR2 Therapeutics does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare TCR2 Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare TCR2 Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
TCR2 Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from TCR2 Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2K7 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -97.50 18.26 33.12
2019-09-30 -96.09 15.74 30.51
2019-06-30 -100.26 13.33 25.12
2019-03-31 -106.53 11.44 21.67
2018-12-31 -61.55 9.48 16.98
2018-09-30 -54.66 9.34 12.71
2017-12-31 -14.86 5.03 8.15
2016-12-31 -10.70 2.26 7.67

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if TCR2 Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if TCR2 Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if TCR2 Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess TCR2 Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
TCR2 Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is TCR2 Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up TCR2 Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • TCR2 Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • TCR2 Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of TCR2 Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • TCR2 Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from TCR2 Therapeutics Company Filings, last reported 3 months ago.

DB:2K7 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 160.45 0.00 158.12
2019-09-30 171.15 0.00 161.01
2019-06-30 182.64 0.00 169.63
2019-03-31 192.05 0.00 161.66
2018-12-31 123.53 0.00 123.17
2018-09-30 130.46 0.00 131.00
2017-12-31 20.78 0.00 19.81
2016-12-31 17.29 0.00 16.34
  • TCR2 Therapeutics has no debt.
  • TCR2 Therapeutics has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • TCR2 Therapeutics has sufficient cash runway for more than 3 years based on current free cash flow.
  • TCR2 Therapeutics has sufficient cash runway for 2 years if free cash flow continues to grow at historical rates of 45.9% each year.
X
Financial health checks
We assess TCR2 Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. TCR2 Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is TCR2 Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from TCR2 Therapeutics dividends.
If you bought €2,000 of TCR2 Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate TCR2 Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate TCR2 Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:2K7 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:2K7 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-05

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as TCR2 Therapeutics has not reported any payouts.
  • Unable to verify if TCR2 Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of TCR2 Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as TCR2 Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess TCR2 Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can TCR2 Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. TCR2 Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of TCR2 Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Garry Menzel
COMPENSATION $3,177,825
AGE 55
TENURE AS CEO 4.3 years
CEO Bio

Dr. Garry E. Menzel, Ph.D. serves as President, Chief Executive Officer and Director of TCR2, Inc. Dr. Menzel served as the Chief Strategy and Financial Officer of Axcella Health, Inc. He is the Independent Director at Aset Therapeutics, Inc. since March 2017. Dr. Menzel served as Chief Business and Strategy Officer at Axcella Health, Inc. since October 19, 2015. Dr. Menzel served as the Chief Financial Officer of DaVita HealthCare Partners Inc. from September 30, 2013 to March 2015. Dr. Menze served as Senior Vice President of Finance at DaVita HealthCare Partners Inc. from September 16, 2013 to September 30, 2013. He served as the Chief Operating Officer and Executive Vice President of Finance at Regulus Therapeutics Inc. (Regulus Therapeutics, LLC) from January 2009 to June 21, 2013. Dr. Menzel served as the Chief Financial Officer of Regulus Therapeutics Inc. Dr. Menzel served as an Executive Vice President of Corporate Development & Finance of Regulus Therapeutics LLC from August 2008 to January 2009. Dr. Menzel served as Senior Vice President and Head of Global Biotechnology Investment Banking of Goldman Sachs, which he joined in 1994. He led the IPO and significant strategic partnerships with Astra Zeneca, GlaxoSmithKline and Sanofi. He served as Global Head of Life Sciences for Credit Suisse. Dr. Menzel served as Consultant of Bain & Company. He served as the Managing Director and Founding Member of the Healthcare Group. Dr. Menzel was employed by Credit Suisse (USA), Inc. and The Goldman Sachs Group, Inc. Dr. Menzel joined Credit Suisse in 2004 and served as its Managing Director. He served a broad range of biotechnology and pharmaceutical clients around the world, raising capital and negotiating merger agreements for some of its most significant transactions. He serves as Director Emeriti of the Institute for Systems Biology. Dr. Menzel serves as an Executive Board Member of the Epilepsy Therapy Project. He served as a Director of Endeavor Pharmaceuticals Inc., since 2001. He is Associate of the Royal College of Science. Dr. Menzel earned a B.Sc. with honors in Biochemistry from Imperial College of Science & Technology in 1985, a Ph.D. in Molecular Biology from the University of Cambridge in 1988 and an M.B.A. from the Stanford Graduate School of Business in 1994.

CEO Compensation
  • Garry's compensation has increased whilst company is loss making.
  • Garry's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the TCR2 Therapeutics management team in years:

2.8
Average Tenure
48
Average Age
  • The tenure for the TCR2 Therapeutics management team is about average.
Management Team

Garry Menzel

TITLE
President
COMPENSATION
$3M
AGE
55
TENURE
4.3 yrs

Robert Hofmeister

TITLE
Chief Scientific Officer
COMPENSATION
$1M
AGE
51
TENURE
3.5 yrs

Alfonso Cardama

TITLE
Chief Medical Officer
COMPENSATION
$1M
AGE
48
TENURE
3.3 yrs

Ian Somaiya

TITLE
Chief Financial Officer
AGE
45
TENURE
1.3 yrs

Carl Mauch

TITLE
Director of Investor Relations & Corporate Communications

Margaret Siegel

TITLE
Head of Legal & Corporate Secretary
TENURE
2.3 yrs

Angela Justice

TITLE
Chief People Officer
AGE
46
TENURE
0.5 yrs
Board of Directors Tenure

Average tenure and age of the TCR2 Therapeutics board of directors in years:

3.2
Average Tenure
60.5
Average Age
  • The tenure for the TCR2 Therapeutics board of directors is about average.
Board of Directors

Ansbert Gadicke

TITLE
Independent Chairman of the Board
AGE
61

Garry Menzel

TITLE
President
COMPENSATION
$3M
AGE
55
TENURE
4.3 yrs

Andrew Allen

TITLE
Independent Director
COMPENSATION
$54K
AGE
52
TENURE
1.3 yrs

Mitch Finer

TITLE
Chairman of the Advisory Board & Independent Director
COMPENSATION
$76K
AGE
60

Neil Gibson

TITLE
Independent Director
COMPENSATION
$55K
AGE
63
TENURE
2.2 yrs

Patrick Baeuerle

TITLE
Director
COMPENSATION
$76K
AGE
61
TENURE
4.9 yrs

Kai Wucherpfennig

TITLE
Member of Advisory Board

Wolfgang Schamel

TITLE
Member of Advisory Board

Marcela Maus

TITLE
Member of Advisory Board

Stephan Grupp

TITLE
Member of the Advisory Board
Who owns this company?
Recent Insider Trading
  • TCR2 Therapeutics individual insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
27. Mar 20 Sell Neil Gibson Individual 13. Mar 20 20. Mar 20 -79,640 €7.42 €-490,735
20. Dec 19 Sell F2 Capital Ltd Company 20. Dec 19 20. Dec 19 -37,756 €15.35 €-562,620
20. Dec 19 Sell Morana Jovan-Embiricos Individual 20. Dec 19 20. Dec 19 -7,100 €15.35 €-105,801
11. Dec 19 Sell F2-Tpo Investments, Llc Company 09. Dec 19 11. Dec 19 -36,482 €15.91 €-580,137
11. Dec 19 Sell F2 Mg Limited Company 09. Dec 19 11. Dec 19 -30,520 €15.91 €-485,329
11. Dec 19 Sell F2 Capital I 2017 Limited Company 09. Dec 19 11. Dec 19 -27,865 €15.91 €-443,109
11. Dec 19 Sell F2 Capital I 2015 Limited Company 09. Dec 19 11. Dec 19 -109,695 €15.91 €-1,744,370
24. Oct 19 Sell F2-Tpo Investments, Llc Company 22. Oct 19 22. Oct 19 -693 €13.61 €-9,428
24. Oct 19 Sell F2 Mg Limited Company 22. Oct 19 22. Oct 19 -580 €13.61 €-7,891
24. Oct 19 Sell F2 Capital I 2017 Limited Company 22. Oct 19 22. Oct 19 -530 €13.61 €-7,211
24. Oct 19 Sell F2 Capital I 2015 Limited Company 22. Oct 19 22. Oct 19 -2,085 €13.61 €-28,366
25. Sep 19 Sell F2-Tpo Investments, Llc Company 20. Sep 19 23. Sep 19 -67,468 €16.31 €-1,099,392
25. Sep 19 Sell F2 Mg Limited Company 20. Sep 19 23. Sep 19 -56,442 €16.31 €-919,724
25. Sep 19 Sell F2 Capital I 2017 Limited Company 20. Sep 19 23. Sep 19 -51,535 €16.31 €-839,764
25. Sep 19 Sell F2 Capital I 2015 Limited Company 20. Sep 19 23. Sep 19 -202,859 €16.31 €-3,305,592
25. Sep 19 Sell Morana Jovan-Embiricos Individual 20. Sep 19 23. Sep 19 -38,017 €16.31 €-619,488
05. Sep 19 Sell Morana Jovan-Embiricos Individual 21. Aug 19 04. Sep 19 -64,104 €15.92 €-995,051
X
Management checks
We assess TCR2 Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. TCR2 Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. The company’s lead product candidates include TC-210, mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which initiated in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma; and TC-110 a TRuC-T cell targeting CD19-positive B-Cell hematological malignancies. Its product candidates in pipeline comprise TC-220, a TRuC-T cell that targets MUC16 positive solid tumors; TC-310, a dual TRuC-T cells targeting both CD19 and CD22; and TC-410, a dual TRuC-T cell targeting both mesothelin and MUC16. The company has a cooperative research and development agreement with the National Cancer Institute to collaborate on the use of TCR2 proprietary T cell receptor Fusion Construct T cells as a cancer therapeutic agent against mesothelin in Phase I/II clinical trial of TC-210. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Details
Name: TCR2 Therapeutics Inc.
2K7
Exchange: DB
Founded: 2015
$155,981,167
24,006,081
Website: http://ww.tcr2.com
Address: TCR2 Therapeutics Inc.
100 Binney Street,
Suite 710,
Cambridge,
Massachusetts, 02142,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS TCRR Common Stock Nasdaq Global Select US USD 14. Feb 2019
DB 2K7 Common Stock Deutsche Boerse AG DE EUR 14. Feb 2019
MUN 2K7 Common Stock Boerse Muenchen DE EUR 14. Feb 2019
Number of employees
Current staff
Staff numbers
83
TCR2 Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/05 23:05
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/03/31
Last earnings filing: 2020/03/30
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.